Last-Resort cancer drug made available for patients with specific gene mutations
Disease control
AVAILABLE
This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …
Sponsor: xCures • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC